New biologic for the treatment of NHL packs one-two punch
Clinicians can now offer their patients with non-Hodgkin?s lymphoma (NHL) therapy that combines targeted radiation with patient-specific dosing. The FDA recently approved tositumomab and iodine I-131 tositumomab (Bexxar, Corixa Corporation/GlaxoSmithKline) for the treatment of patients with CD20-positive, follicular NHL, with and without transformation, whose disease is refractory to rituxamab (Rituxan, Genentech) and has relapsed following chemotherapy. Training can be requested and orders placed by calling (877) 423-9927. Corixa recently began supplying Bexxar to cancer treatment centers.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
